PMID- 34551206
OWN - NLM
STAT- MEDLINE
DCOM- 20220309
LR  - 20221207
IS  - 2040-1124 (Electronic)
IS  - 2040-1116 (Print)
IS  - 2040-1116 (Linking)
VI  - 13
IP  - 3
DP  - 2022 Mar
TI  - Dipeptidyl peptidase-4 inhibitor and insulin combination treatment in type 2 
      diabetes and chronic kidney disease: A meta-analysis.
PG  - 468-477
LID - 10.1111/jdi.13675 [doi]
AB  - AIMS/INTRODUCTION: The union of dipeptidyl peptidase-4 inhibitors and insulin in 
      patients with type 2 diabetes and chronic kidney disease provides satisfactory 
      glucose management without increasing adverse events (AEs). This research 
      appraised the therapeutic effect and safety of combination therapy in patients 
      with type 2 diabetes and chronic kidney disease. MATERIALS AND METHODS: We 
      carried out a meta-analysis of randomized controlled trials to analyze AEs, 
      hypoglycemia, serious AEs, severe hypoglycemia, estimated glomerular filtration 
      rate, fasting plasma glucose, glycated hemoglobin, insulin dose, low-density 
      lipoprotein cholesterol, uric acid and weight between combination treatment 
      groups and control groups by searching the Cochrane Library, Excerpta Medica 
      Database (Embase), PubMed and Web of Science databanks until October 2020. 
      RESULTS: Five studies (6 trials, 1,278 participants) met the inclusion criteria. 
      The evidence quality ranged from moderate to high. Glycated hemoglobin 
      (standardized mean difference -0.29, 95% confidence interval -0.44 to -0.14) and 
      insulin dose (standardized mean difference -0.16, 95% confidence interval -0.29 
      to -0.02) were obviously smaller in the combination cure patients than in the 
      control patients. Compared with the control groups, combination treatment did not 
      increase AEs, hypoglycemia, serious AEs or severe hypoglycemia. CONCLUSIONS: This 
      study showed the effectiveness and safety of dipeptidyl peptidase-4 inhibitors 
      bonded with insulin in patients with type 2 diabetes and chronic kidney disease, 
      but the protective actions of this cure on kidney and cardiovascular outcomes, as 
      well as the functions of other dipeptidyl peptidase-4 inhibitors, need to be 
      affirmed by more good-quality randomized controlled trials.
CI  - (c) 2021 The Authors. Journal of Diabetes Investigation published by Asian 
      Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, 
      Ltd.
FAU - Zhou, Xianling
AU  - Zhou X
AUID- ORCID: 0000-0002-2087-3322
AD  - Department of Nephrology, The First Affiliated Hospital of Jinan University, 
      Guangzhou, China.
FAU - Shi, Heng
AU  - Shi H
AD  - Department of Nephrology, The First Affiliated Hospital of Jinan University, 
      Guangzhou, China.
FAU - Zhu, Shiping
AU  - Zhu S
AD  - Department of Traditional Chinese Medicine, The First Affiliated Hospital of 
      Jinan University, Guangzhou, China.
FAU - Wang, Haixia
AU  - Wang H
AD  - Department of Traditional Chinese Medicine, The First Affiliated Hospital of 
      Jinan University, Guangzhou, China.
FAU - Sun, Shengyun
AU  - Sun S
AD  - Department of Traditional Chinese Medicine, The First Affiliated Hospital of 
      Jinan University, Guangzhou, China.
LA  - eng
GR  - 20203005/Research Project of Guangdong Provincial Bureau of Traditional Chinese 
      Medicine/
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20211020
PL  - Japan
TA  - J Diabetes Investig
JT  - Journal of diabetes investigation
JID - 101520702
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use
MH  - Glycated Hemoglobin/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - *Renal Insufficiency, Chronic/complications/drug therapy
MH  - Treatment Outcome
PMC - PMC8902402
OTO - NOTNLM
OT  - Chronic kidney disease
OT  - Dipeptidyl peptidase-4 inhibitor
OT  - Type 2 diabetes
EDAT- 2021/09/23 06:00
MHDA- 2022/03/11 06:00
PMCR- 2022/03/01
CRDT- 2021/09/22 17:35
PHST- 2021/09/07 00:00 [revised]
PHST- 2021/07/31 00:00 [received]
PHST- 2021/09/18 00:00 [accepted]
PHST- 2021/09/23 06:00 [pubmed]
PHST- 2022/03/11 06:00 [medline]
PHST- 2021/09/22 17:35 [entrez]
PHST- 2022/03/01 00:00 [pmc-release]
AID - JDI13675 [pii]
AID - 10.1111/jdi.13675 [doi]
PST - ppublish
SO  - J Diabetes Investig. 2022 Mar;13(3):468-477. doi: 10.1111/jdi.13675. Epub 2021 
      Oct 20.